Testing a new treatment for nerve pain in the eye
Part of Eyes & vision, Pain clinical trials.
This study tests a new non-invasive treatment (Quantum Molecular Resonance) to see if it can reduce pain and help damaged nerves in the eye heal. It may help people with long-lasting eye pain caused by nerve damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years or older.
- You must have been diagnosed with nerve pain in the eye (symptoms like burning, stinging, or sensitivity to light, with few visible signs on exam).
- You must agree to receive all eye exams required for the study.
- You cannot be pregnant.
- You cannot have an active implanted device like a pacemaker.
- You cannot have had eye surgery in the last month or an eye infection in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational eye drop called urcosimod to see if it can reduce pain from a condition called neuropathic corneal pain, which happens when the nerves in the clear front part of your eye are damaged. If you join, you would use the eye drops for a period and report your pain levels.
This trial tests whether special eye drops made from cord plasma (a blood product) can reduce chronic eye pain caused by damaged nerves in the cornea (the clear front part of your eye). You may qualify if you have had eye pain for at least 3 months without obvious surface damage.
This study tests a new scanning technology (terahertz) to see if it can detect and measure corneal scars and swelling (edema). If you have one of these conditions, you may help validate a faster, non-invasive way to monitor your eye health.
This trial tests a cooling treatment (EyeCool) for people with long-term pain on the eye's surface. It looks at how the treatment affects the eye's surface structure and inflammation after standard care hasn't worked well enough.
This trial tests an experimental eye drop (STSP-0902) for a condition called neurotrophic keratitis, where the cornea (the clear front part of the eye) gets scratches or sores because nerves are damaged. The drop contains a growth factor to help the eye heal. You might be eligible if you have a persistent scratch or sore on your cornea that has not improved for at least a week.
This trial tests a new eye drop (acoltre mon) to see if it helps people who have both dry eyes and nerve-related eye pain. The drops may increase tear production and reduce burning or light sensitivity.
Hear when a new Neuropathic Corneal Pain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.